Early diagnosis of pulmonary arterial hypertension improves five-year survival by 42%, compared with delayed diagnosis, a ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

In treatment-naïve patients with PAH, initial monotherapy improves exercise capacity, hemodynamics, and outcomes when compared with those noted among untreated patients. In patients who are newly ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

Winter Haven resident Glenda Johns’ battle with heart failure — marked by increasing weakness and frequent hospital stays — is a textbook case of how the condition can consume patients’ lives. “Every ...

Pulmonary thromboendarterectomy is a surgery used to treat chronic thromboembolic pulmonary hypertension. It’s the treatment of choice for this condition. Chronic thromboembolic pulmonary hypertension ...